Item 7.01. Regulation FD Disclosure.

Acer Therapeutics Inc. (the "Company") has updated its Corporate Presentation that will be available on the Investor Relations page of the Company's website at https://acertx.com/investor-relations and will be used at investor and other meetings. A copy of the updated Corporate Presentation is furnished as Exhibit 99.1 and incorporated herein by reference. The Company does not undertake to update this presentation.




Item 8.01. Other Events.

On December 30, 2019, the Company submitted a Formal Dispute Resolution Request to the Office of New Drugs of the United States Food and Drug Administration ("FDA"), appealing the previously announced Complete Response Letter that the Company received from the FDA on June 24, 2019 regarding its New Drug Application for EDSIVOTM (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen (COL3A1) mutation.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01.Financial Statements and Exhibits.





(d) Exhibits



    Exhibit
      No.                               Description


    99.1        Acer Therapeutics Inc. Corporate Presentation, January 2020.







2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses